Y0001642
卡培他滨
European Pharmacopoeia (EP) Reference Standard
别名:
5′-脱氧-5-氟-N-[（戊氧基）羰基]胞苷, Ro-9-1978
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H22FN3O6
化学文摘社编号:
分子量:
359.35
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
capecitabine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C
InChI
1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
InChI key
GAGWJHPBXLXJQN-UORFTKCHSA-N
基因信息
human ... TYMS(7298)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Capecitabine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。
卡培他滨是一种抗癌药物，是去氧氟尿苷的前药，在肿瘤部位代谢为5-氟尿嘧啶。 卡培他滨的激活遵循具有三个酶促步骤和两个中间代谢物5′-脱氧-5-氟胞苷（5′-DFCR）和5′-脱氧-5-氟尿苷（5′-DFUR）的途径，形成5-氟尿嘧啶。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
预防措施声明
危险分类
Carc. 1B - Muta. 2 - Repr. 1B
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
A Iu Abrosimov et al.
Arkhiv patologii, 75(6), 27-31 (2014-03-15)
The pathomorphism of rectal cancer (RC) was studied in 99 patients who received neoadjuvant chemoradiotherapy using two drugs (5-fluorouracil and xeloda). A morphological study indicated the qualitatively similar manifestations of pathomorphism (tumor necrosis, inflammation, and sclerosis) which were more pronounced
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Tim Meyer et al.
European journal of cancer (Oxford, England : 1990), 50(5), 902-911 (2014-01-22)
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an
Mitsuhiro Tomoda et al.
Anticancer research, 34(1), 191-194 (2014-01-10)
Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy. In the present study, we administered monthly chemotherapy and aimed to evaluate the usefulness of the specific treatment schedule in patients with
Dermatomyositis associated with capecitabine in the setting of malignancy.
Frank W Chen et al.
Journal of the American Academy of Dermatology, 70(2), e47-e48 (2014-01-21)
Karen-Lise G Spindler et al.
Anticancer research, 34(2), 845-850 (2014-02-11)
We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement. Patients' inclusion criteria included histopathologically-verified mCRC refractory to standard chemotherapy, adequate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持